DMAC Earnings & Financial Statements
DiaMedica Therapeutics Inc.
$7.96
+$0.30(+3.92%)
50
Overall
40
Value
75
Tech
36
Quality
Market Cap
$413.07M
Volume
39.81K
52W Range
$5.25 - $10.42
Target Price
$15.50
DMAC earnings and financial statements: DiaMedica Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DMAC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$34.40M | -$26.68M | -$21.27M | -$14.00M | -$13.65M |
| EBITDA | -$32.70M | -$24.38M | -$19.31M | -$13.98M | -$13.62M |
| Net income | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -$13.59M |
| EPS (diluted) | $-0.70 | $-0.60 | $-0.60 | $-0.52 | $-0.65 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $61.37M | $46.34M | $54.16M | $34.40M | $45.55M |
| Total liabilities | $5.26M | $5.63M | $3.10M | $2.57M | $1.53M |
| Shareholders’ equity | $56.11M | $40.72M | $51.06M | $31.83M | $44.02M |
| Cash and equivalents | $15.65M | $3.02M | $4.54M | $4.73M | $4.71M |
| Long-term debt | $128.0K | $237.0K | $317.0K | $400.0K | $3.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$29.06M | -$22.08M | -$18.73M | -$11.51M | -$12.25M |
| Capital expenditure | -$40.0K | -$25.0K | -$24.0K | -$81.0K | -$22.0K |
| Free cash flow | -$29.10M | -$22.10M | -$18.75M | -$11.59M | -$12.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DMAC | $7.96 | +3.9% | 39.81K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get DiaMedica Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW